|Free Dividend Report|
|Stock Splits Calendar|
|BBI Stock Split History|
|Preferred Stock Newsletter|
|Top Option Ideas|
|BBI Message Board|
Brickell Biotech (BBI) has 1 split in our BBI split history database. The split for BBI took place on September 03, 2019. This was a 1 for 7 reverse split, meaning for each 7 shares of BBI owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split.
When a company such as Brickell Biotech conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the BBI split history from start to finish, an original position size of 1000 shares would have turned into 142.857142857143 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Brickell Biotech shares, starting with a $10,000 purchase of BBI, presented on a split-history-adjusted basis factoring in the complete BBI split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-27.43%|
|About Brickell Biotech|
|Brickell Biotech is a clinical-stage pharmaceutical company focused on the development of prescription therapeutics for the treatment of debilitating skin diseases. Co.'s pipeline consists of therapeutics for hyperhidrosis and other prevalent dermatological conditions. Co.'s Sofpironium bromide is a topical anticholinergic product candidate, developed for once-daily treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are intended to exert their action topically and are metabolized once absorbed into the blood. According to our BBI split history records, Brickell Biotech has had 1 split.|
|BBI Split History Table|
|09/03/2019||1 for 7|
|Energy Stock Splits|
|BBI is categorized under the Energy sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: BBI shares outstanding history